Minimally Invasive Active Release of Septa Bands for Cellulite and Connective Tissue Release for Fibrosis Treatment in Body Contouring Surgery
NCT ID: NCT06791564
Last Updated: 2025-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
150 participants
INTERVENTIONAL
2024-01-15
2025-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions this study seeks to answer are:
* Does AVELI safely reduce cellulite and fibrotic tissue without causing serious adverse events?
* How effective is AVELI in improving patient-reported outcomes and aesthetic appearance?
Through this study, the study team aims to evaluate the safety and effectiveness of AVELI.
The study procedures include:
* Baseline data collection of sociodemographic variables. Data collection of surgical variables, adverse events, and satisfaction scores.
* All patients will undergo the standardized High-Definition Liposculpture technique, with AVELI applied to all identified cellulite and/or fibrosis release.
* Photographic and 3D imaging preoperatively and at follow-ups (1, 3, 6, and 9 months).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Forceps vs. Snare IVC Filter Removal
NCT04092192
Efficacy on Pain Following a Procedure for Injecting Sclerotherapeutic Foam Into the Great Saphenous Vein
NCT01368159
Evaluation of the OsciPulse Rapid Cycling Compression Device Effects on Venous Blood Flow
NCT05087108
Evaluation of a Dual Action Pneumatic Compression Device: Patient Ease of Use and Comfort
NCT02015221
Treatment of Varicose Veins With the ELVeS® Radial® 2ring Slim Fiber. Are There Limitations?
NCT03810677
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Ethical Considerations:
* IRB Approval: The study will adhere to the Declaration of Helsinki principles and will be approved by an Institutional Review Board (IRB).
* Informed Consent: Participants will be provided comprehensive information about study procedures, risks, and benefits, and written consent will be obtained.
* Data Confidentiality: All participant data will be anonymized and securely stored.
Eligible patients will be approached, the study aims, objectives, procedures, and voluntary participation will be explained. In case patient consent to participate, a written informed consent will be signed. The patients will be comprehensively evaluated by the plastic surgeon, and assigned to a group based on their individual physical evaluation findings: Cellulite Group, Fibrosis Group, Fibrosis and Cellulite Group.
Study Locations:
* Dhara Clinic (Bogota, Colombia)
* Miami Aesthetic Center (Miami, FL - USA)
Data Collection:
* Demographic, Clinical, and surgical variables are going to be collected in an Excel-based password protected database.
* Other procedure related variables are also going to be collected in the same database, including pain assessment in the immediate postoperative, hemoglobin and hematocrit levels, time to discharge, and complications \& management.
* 3D photographic analysis will be employed to analyze preoperative, and postoperative images at 1, 3, 6 and 9 months post procedure. Then the changes will be objectively compared using Quantificare Photographical Software, through the different timepoints to evaluate the objective contour defects and postoperative improvement changes.
* Satisfaction Scores: Global Aesthetic Improvement Scale (GAIS) evaluated at least 3 months postoperatively.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cellulite group (CG)
Patients with any degree of clinically evident cellulite undergoing HDL + AVÉLI treatment for Cellulite.
AVELI
Minimally invasive method for selectively identifying and manually releasing specific septa responsible for causing cellulite depressions.
Fibrosis Group (FG)
Patients with any degree of fibrosis undergoing non-primary HDL + AVÉLI release of fibrotic tissue.
AVELI
Minimally invasive method for selectively identifying and manually releasing specific septa responsible for causing cellulite depressions.
Fibrosis and Cellulite Group (FCG)
Patients with any degree of clinically evident cellulite AND fibrosis undergoing non-primary HDL + AVÉLI treatment for both.
AVELI
Minimally invasive method for selectively identifying and manually releasing specific septa responsible for causing cellulite depressions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AVELI
Minimally invasive method for selectively identifying and manually releasing specific septa responsible for causing cellulite depressions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-gender specific.
* American Association of Anesthesiologist Risk Assessment (ASA) ≤ 2.
* Body Mass Index (BMI) ≥20 and ≤ 32 kg/m2.
* Patients with any degree of clinically evident cellulite in any body area.
* Patients with prior liposuction procedures with any degree of fibrosis in any body area.
* Patients undergoing additional procedures such as, but not limited to: Rhinoplasty, Mammaplasty, Mastopexy, mini tummy tuck, full tummy tuck, brachioplasty, thighplasty, fat grafting. The procedure could not be related to the treatment of fibrosis or cellulite.
Exclusion Criteria
* Patients requiring other devices/drugs for skin contraction and/or cellulite treatment for the next 6 months (RF, US, Enzymes, etc.).
* Patients undergoing Face Lift procedures.
* Patients with any history of abnormal scarring and/or hypertrophic scars and or keloids.
* Patients with Caprini score ≥ 8.
* Patients with past medical history of connective tissue disease with active disease and/or recent relapse.
* Patients with past medical history thromboembolic disease or any other condition with an increased risk of coagulopathy (i.e., SLE, RA, APS).
* Patients using aspirin or any anticoagulant within 14 days and 5 days prior to surgery, respectively.
* Patients with a PMH of epilepsy or any epileptic syndrome and or vascular disease.
* Patients with any chronic disease non-compliant with treatment or non-adequately controlled.
* Positive pregnancy test or planning on getting pregnant in the next 6 months.
* Patients with fever or any other symptoms/signs of infection.
* Active smokers or chronic smokers with recent quit (≤ 4-8 weeks).
* Patients with prothrombin time (PT) and/or activated partial thromboplastin time (aPTT) \>1.5 times baseline.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Total Definer Research Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alfredo Hoyos
MD, Plastic Surgeon | Total Definer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Miami Aesthetic
Miami, Florida, United States
Dhara Clinic
Bogotá, DC, Colombia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Stevens WG, Green JB, Layt C, Kaminer MS, Harrington J, Fan L, Wall HC, Fabi S, Magnusson MR. Multicenter Pivotal Study Demonstrates Safety and Efficacy of a New Cellulite Procedure: Final Results at 12 Months. Aesthet Surg J. 2023 Mar 15;43(4):455-466. doi: 10.1093/asj/sjac291.
Stevens WG, Kaminer MS, Fabi SG, Fan L. Study of a New Controlled Focal Septa Release Cellulite Reduction Method. Aesthet Surg J. 2022 Aug 1;42(8):937-945. doi: 10.1093/asj/sjac010.
Danilla S, Babaitis RA, Jara RP, Quispe DA, Andrades PR, Erazo CA, Albornoz CR, Sepulveda SL. High-Definition Liposculpture: What are the Complications and How to Manage Them? Aesthetic Plast Surg. 2020 Apr;44(2):411-418. doi: 10.1007/s00266-019-01475-6. Epub 2019 Aug 20.
Bass LS, Kaminer MS. Insights Into the Pathophysiology of Cellulite: A Review. Dermatol Surg. 2020 Oct;46 Suppl 1(1):S77-S85. doi: 10.1097/DSS.0000000000002388.
Friedmann DP, Vick GL, Mishra V. Cellulite: a review with a focus on subcision. Clin Cosmet Investig Dermatol. 2017 Jan 7;10:17-23. doi: 10.2147/CCID.S95830. eCollection 2017.
Gabriel A, Chan V, Caldarella M, Wayne T, O'Rorke E. Cellulite: Current Understanding and Treatment. Aesthet Surg J Open Forum. 2023 Jun 21;5:ojad050. doi: 10.1093/asjof/ojad050. eCollection 2023.
Ferry AM, Chamata E, Dibbs RP, Rappaport NH. Avoidance and Correction of Deformities in Body Contouring. Semin Plast Surg. 2021 May;35(2):110-118. doi: 10.1055/s-0041-1727207. Epub 2021 Jun 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Aveli
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.